Complete financial analysis of Kangji Medical Holdings Limited (9997.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kangji Medical Holdings Limited, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Growthpoint Properties Limited (GWWTF) Income Statement Analysis – Financial Results
- Bankinter, S.A. (BKIMF) Income Statement Analysis – Financial Results
- Glotech Industrial Corp. (5475.TWO) Income Statement Analysis – Financial Results
- CarMax, Inc. (KMX) Income Statement Analysis – Financial Results
- Valiant Laboratories Limited (VALIANTLAB.BO) Income Statement Analysis – Financial Results
Kangji Medical Holdings Limited (9997.HK)
About Kangji Medical Holdings Limited
Kangji Medical Holdings Limited, through its subsidiaries, designs, develops, manufactures, and sale of minimally invasive surgical instruments and accessories in China. It offers disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, ultrasonic scalpels, and other types of disposable hand-held instruments; and reusable trocars, reusable forceps, and other reusable products. The company's products are used in obstetrics and gynecology, general surgery, urology, and thoracic surgery specialties. It primarily sells products to a network of distributors. The company was founded in 2004 and is headquartered in Hangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 926.02M | 786.37M | 690.26M | 511.49M | 503.47M | 353.67M | 247.51M |
| Cost of Revenue | 184.82M | 151.12M | 127.34M | 80.02M | 80.29M | 64.37M | 47.80M |
| Gross Profit | 741.20M | 635.25M | 562.93M | 431.47M | 423.18M | 289.30M | 199.71M |
| Gross Profit Ratio | 80.04% | 80.78% | 81.55% | 84.36% | 84.05% | 81.80% | 80.69% |
| Research & Development | 127.55M | 66.02M | 36.00M | 25.22M | 17.38M | 14.86M | 10.48M |
| General & Administrative | 100.27M | 70.89M | 62.06M | 45.69M | 25.58M | 12.59M | 8.07M |
| Selling & Marketing | 69.84M | 53.37M | 46.52M | 48.89M | 41.36M | 20.51M | 11.83M |
| SG&A | 170.11M | 123.21M | 109.19M | 94.58M | 67.00M | 33.09M | 19.90M |
| Other Expenses | 0.00 | -26.47M | -3.69M | -25.55M | -1.16M | 61.00K | -3.72M |
| Operating Expenses | 298.73M | 140.23M | 79.82M | 138.50M | 48.68M | 40.75M | 34.51M |
| Cost & Expenses | 483.55M | 291.35M | 207.16M | 218.52M | 128.97M | 105.12M | 82.32M |
| Interest Income | 91.83M | 68.13M | 51.39M | 17.10M | 16.70M | 6.96M | 1.17M |
| Interest Expense | 2.26M | 1.88M | 196.00K | 42.00K | 0.00 | 2.00K | 1.00K |
| Depreciation & Amortization | 22.11M | 21.63M | 11.86M | 8.20M | 6.85M | 6.26M | 6.47M |
| EBITDA | 464.58M | 586.65M | 427.25M | 319.14M | 345.20M | 267.42M | 168.65M |
| EBITDA Ratio | 50.17% | 58.56% | 61.90% | 62.39% | 68.56% | 75.44% | 68.33% |
| Operating Income | 442.47M | 446.02M | 417.74M | 311.67M | 338.80M | 260.55M | 162.64M |
| Operating Income Ratio | 47.78% | 56.72% | 60.52% | 60.93% | 67.29% | 73.67% | 65.71% |
| Total Other Income/Expenses | 146.30M | 117.50M | 116.76M | -1.59M | 52.40M | 614.00K | -3.02M |
| Income Before Tax | 588.77M | 563.14M | 534.50M | 310.08M | 391.19M | 261.16M | 162.17M |
| Income Before Tax Ratio | 63.58% | 71.61% | 77.43% | 60.62% | 77.70% | 73.84% | 65.52% |
| Income Tax Expense | 136.48M | 101.97M | 77.71M | 50.93M | 64.46M | 37.37M | 23.70M |
| Net Income | 504.02M | 478.74M | 456.79M | 250.30M | 206.44M | 146.70M | 117.71M |
| Net Income Ratio | 54.43% | 60.88% | 66.18% | 48.93% | 41.00% | 41.48% | 47.56% |
| EPS | 0.43 | 0.40 | 0.37 | 0.26 | 0.20 | 0.12 | 0.09 |
| EPS Diluted | 0.43 | 0.40 | 0.37 | 0.26 | 0.20 | 0.12 | 0.09 |
| Weighted Avg Shares Out | 1.17B | 1.21B | 1.22B | 952.80M | 1.03B | 1.25B | 1.25B |
| Weighted Avg Shares Out (Dil) | 1.17B | 1.21B | 1.23B | 963.78M | 1.03B | 1.25B | 1.25B |
Source: https://incomestatements.info
Category: Stock Reports